GENE ONLINE|News &
Opinion
Blog

2021-09-30| Special

What Does It Take for a Cell & Gene Therapy Program to Go Commercial?

by Sahana Shankar
Share To
In the past decade, cell and gene therapies have debuted successfully for various therapeutic areas and are no longer restricted to academic research trials. Therefore, building a cell and gene therapy company would require strategic and organizational capabilities that are slightly different from the conventional pharmaceutical landscape.

At the Reuters Events Cell & Gene Therapy Conference, several eminent speakers shared their views on what companies must consider while commercializing cell and gene therapies.

The session titled ‘Build and standardize an agile commercialization network’ was moderated by GeneOnline’s senior editor, Rajaneesh K. Gopinath. The panel consisted of the following experts.

Christine Strobele, Senior Director, US Launch lead- darvadstrocel at Takeda Sandra Anderson, Senior VP, Commercialization, and Strategy, Innomar Strategies Rita Johnson-Greene, VP Sales and Qualified Treatment Centers, bluebird bio Bethany Rogers,  VP Marketing- tabelecleucel, Atara Biotherapeutics

GO Prime with only $1.49 now

LATEST
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!